Market Overview

Why Morgan Stanley Is Buying The Dip In Eli Lilly

Why Morgan Stanley Is Buying The Dip In Eli Lilly

Eli Lilly And Co (NYSE: LLY) stock has pulled back in recent months, rendering its valuation more attractive, according to a Morgan Stanley analyst. 

The Lilly Analyst: David Risinger upgraded Eli Lilly from Equal-weight to Overweight and increased the price target from $157 to $176.

The Lilly Thesis: The 9% pullback in Lilly shares seen since June 30 was mainly due to disappointing second-quarter results, the management downplaying COVID-19 antibody opportunities and concern about an impending readout on high-dose Ozempic from rival Novo Nordisk A/S (NYSE: NVO), Risinger said in a Thursday note. 

This has rendered the forward P/E in line with the five-year average, the analyst said. 

Fundamentally, Lilly is likely to outperform, driven by long-term growth prospects, positive Phase 3 tirzepatide results starting in the fourth quarter and rising enthusiasm for its Alzheimer's pipeline, he said.

The consensus estimates underappreciate Lilly's long-term revenue and EPS growth potential, Risinger said.

Morgan Stanley's 2025 revenues and EPS estimates are both 7% above the consensus, the analyst said. 

Tirzepatide could be best-in-class for glucose lowering, weight loss and cardiovascular risk, he said. 

Risinger sees peak sales potential for the candidate as reaching $10 billion. Beyond diabetes, tirzepatide could become a leading prescription drug for obesity, the analyst said.

Among other catalysts, Lilly has four proof-of-concept results from its early stage diabetes pipeline coming in 2021, he said. 

"Lilly's Alzheimer's pipeline represents an inexpensive call option, in our view."  

The analyst estimates only $725 million in risk-adjusted Alzheimer's pipeline sales in 2025.

An FDA approval for Biogen Inc's (NASDAQ: BIIB) highly controversial Alzheimer's investigational drug aducanumab could be a perception positive for Lilly, as a regulatory nod could suggest a low regulatory bar for Alzheimer's, he said.

Lilly has two Alzheimer's candidates — N3PG and tau antibody — set to report Phase 2 data in 2021, Risinger said.

With Morgan Stanley assuming only 5% odds of success for each, the risk-reward is skewed to the upside, the analyst said.

As such, Morgan Stanley increased its estimates for Lilly's key franchises and extended its model.

LLY Price Action: At last check, Lilly shares were down 0.84% at $148.30. 

Related Links:

The Week Ahead In Biotech: Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Latest Ratings for LLY

Dec 2020Wolfe ResearchUpgradesPeer PerformOutperform
Nov 2020MizuhoMaintainsNeutral
Nov 2020BernsteinInitiates Coverage OnMarket Perform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: David Risinger Morgan StanleyAnalyst Color Biotech Upgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at